NRX Pharmaceuticals (NRXP) Revenue (2025 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly Revenue came in at $1.1 million in Q2 2026, little changed quarter-over-quarter from $1.1 million in Q1 2026.
Powered by 
Analysis
NRX Pharmaceuticals (NRXP) Revenue (2025 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Revenue for 2 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Revenue changed N/A year-over-year to $1.1 million in Q2 2026; TTM through Jun 2026 was $3.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.2 million, changed N/A from the prior year.
- Revenue was $1.1 million for Q2 2026 at NRX Pharmaceuticals, roughly flat from $1.1 million in the prior quarter.
- Over five years, Revenue peaked at $1.1 million in Q2 2026 and troughed at $242000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.71 Bn | 192.72 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.26 Bn | 177.08 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 131.29 Bn | 123.43 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.82 Bn | 73.83 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.94 Bn | 48.80 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.34 Bn | 30.03 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.87 Bn | 30.58 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.02 Bn | 29.02 Bn | 1.16 Mn | 1.44 Mn |
| 10 | NRX Pharmaceuticals | 129.14 Mn | 102.44 Mn | 426,000.00 | 1.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 983,000.00 |
| Sep 30, 2025 | 242,000.00 |